Page 14 - தேடலை பரிசோதனை இணைக்கப்பட்டது News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Global Preimplantation Genetic Testing Industry (2020 to 2027) - Key Market Drivers and Trends
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), Alexion Pharmaceuticals, Inc (NASDAQ:ALXN) - The Daily Biotech Pulse: KemPharm Receives $10M Milestone Payment, Zymergen, Neuropace Debut On Nasdaq, Renalytix Wins US Government Contract, 2 IPOs
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
SECAUCUS, N.J., April 22, 2021 /PRNewswire/ Quest Diagnostics Incorporated (NYSE: DGX), the world s leading provider of diagnostic information services, announced today financial results for the first quarter ended March 31, 2021. Quest had a very strong first quarter, with our base business continuing its recovery to near pre-pandemic levels, said Steve Rusckowski, Chairman, CEO and President, Quest Diagnostics. Contributions from acquisitions and Professional Lab Services relationships accelerated growth in the base business and helped offset the reduction in demand for COVID-19 testing, which was in line with industry trends. In March, for the first time since the pandemic began, monthly organic revenue in the base business grew versus our 2019 baseline. As we noted at our recent Investor Day, Quest is well positioned to grow as the U.S. exits the pandemic and people return to normal activities and address the routine care issues th
iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), Abbott Laboratories (NYSE:ABT) - The Week Ahead In Biotech: Johnson & Johnson, Biogen Earnings, Neurology Conference And IPOs
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
ResearchAndMarkets.com s offering.
This report highlights that the market is projected to reach $40.6 billion by 2030. The study also highlights that the market is set to witness a CAGR of 6.09% during the period 2020-2030.
The market is driven by the need for the development of an advanced solution based on various technologies such as next-generation sequencing, in-situ hybridization, and polymerase chain reaction for cancer research in various applications such as diagnosis, prognosis, and treatment.
The market is favored by the development of high-throughput, rapid, sensitive, and multi-parametric solutions for prognosis, diagnostics, and treatment. The gradual increase in the prevalence of cancer globally has furthered the solid tumor testing market.